Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
87
datasets available to search
ShareScore release 0.9.0
Dataset results
87 results for “mucopolysaccharidosis”
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
ClinicalTrials.gov study NCT00418821. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
ClinicalTrials.gov study NCT05073783. IPD Sharing: YES. Countries: 1. Publications: 0.
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
ClinicalTrials.gov study NCT01515956. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
ClinicalTrials.gov study NCT02230566. IPD Sharing: Not stated. Countries: 1. Publications: 5.
An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis
ClinicalTrials.gov study NCT01856218. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I
ClinicalTrials.gov study NCT00912925. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA
ClinicalTrials.gov study NCT00884949. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
ClinicalTrials.gov study NCT01242111. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of JR-171 in Patients With Mucopolysaccharidosis I
ClinicalTrials.gov study NCT04227600. IPD Sharing: NO. Countries: 3. Publications: 0.
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
ClinicalTrials.gov study NCT00146770. IPD Sharing: Not stated. Countries: 7. Publications: 2.
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
ClinicalTrials.gov study NCT01275066. IPD Sharing: Not stated. Countries: 17. Publications: 1.
A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)
ClinicalTrials.gov study NCT02432144. IPD Sharing: Not stated. Countries: 4. Publications: 3.
Study of rhASB in Patients With Mucopolysaccharidosis VI
ClinicalTrials.gov study NCT00104234. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
ClinicalTrials.gov study NCT00069641. IPD Sharing: Not stated. Countries: 4. Publications: 2.
Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
ClinicalTrials.gov study NCT02418455. IPD Sharing: Not stated. Countries: 3. Publications: 3.
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
ClinicalTrials.gov study NCT01415427. IPD Sharing: Not stated. Countries: 20. Publications: 3.
STROBE checklist for 'Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study'
<p>STROBE checklist for ‘Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study’</p>
Underlying data for Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study
<p>Underlying data for Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study</p>
Underlying data for Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study
<p>Underlying data for Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study</p>
STROBE checklist for 'Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study.'
<p>STROBE checklist for 'Prevalence Rates of Mucopolysaccharidosis in Iraq: a retrospective cross-sectional observational study.'</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.